Article
Pharmacology & Pharmacy
Lara Magro, Elena Arzenton, Roberto Leone, Marilisa Giustina Stano, Michele Vezzaro, Annette Rudolph, Irene Castagna, Ugo Moretti
Summary: The study found that about one-third of patients exposed to potential drug-drug interactions actually experienced serious adverse drug reactions, and that a spontaneous reporting database can be used to identify and describe ADRs caused by drug-drug interactions. Among these ADRs, warfarin was the most frequently reported interacting drug and the most common ADRs were gastrointestinal or cerebral hemorrhagic events.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Laura Lopez-Valverde, Elia Domenech, Marc Roguera, Ignasi Gich, Magi Farre, Carlos Rodrigo, Eva Montane
Summary: The study analyzed spontaneously reported ADRs in pediatric patients between 2010 and 2020, finding that nervous system disorders were the most common type of ADR in pediatric patients, and medication errors were more frequent in patients under two years of age.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Louis Letinier, Amandine Ferreira, Alexandre Marceron, Marina Babin, Joelle Micallef, Ghada Miremont-Salame, Antoine Pariente
Summary: The study found that hemorrhage was the most common clinical manifestation of serious adverse drug reactions resulting from drug-drug interactions reported in France, followed by renal failure, pharmacokinetic alteration, and cardiac arrhythmias. More than one-third of serious adverse drug reactions involved at least three drugs.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Zhiming Jiao, Zhanchun Feng, Ziqi Yan, Jinwen Zhang, Gang Li, Ganyi Wang, Qianyu Wang, Da Feng
Summary: This study collected 431 ADR reports related to antineoplastic drugs in pediatric patients, finding that myelosuppression was the most frequent ADR. The median age of patients was six years, with higher reporting rates in the age group of 1-3 years. Three off-label ADRs were identified through signal mining, calling for further research and attention.
FRONTIERS IN ONCOLOGY
(2021)
Review
Public, Environmental & Occupational Health
Joel Fossouo Tagne, Reginald Amin Yakob, Thu Ha Dang, Rachael Mcdonald, Nilmini Wickramasinghe
Summary: Despite existing national and international guidelines, there is significant variability in the standards of adverse drug reaction (ADR) reporting among healthcare facilities. There is room for improvement in ADR reporting rates among consumers and healthcare professionals. A thorough assessment of barriers and enablers to ADR reporting at the primary healthcare level is necessary, and interventions such as the black triangle scheme and GuildLink may benefit from further improvement and awareness programs.
JMIR PUBLIC HEALTH AND SURVEILLANCE
(2023)
Article
Dentistry, Oral Surgery & Medicine
Birita Sofia Ellefsen, Kristine Ron Larsen, Jesper Reibel, Camilla Kragelund
Summary: Post-marketing pharmacosurveillance is crucial for minimizing harm to patients from marketed drugs. Oral adverse drug reactions (OADRs) are underreported, and their inclusion in drug summary of product characteristics (SmPC) is limited. The reporting pattern of healthcare professionals is influenced by community debates, professional circles, and drug SmPC information. Systematic, reliable, and consistent reporting is essential to avoid skewed information and all healthcare professionals should be educated to recognize and report suspected adverse drug reactions.
Article
Chemistry, Medicinal
Anne T. M. Dittrich, Nori J. L. Smeets, Emma F. M. de Jong, Juliet L. Kamink, Yvet Kroeze, Jos M. Th Draaisma, Eugene P. van Puijenbroek, D. Maroeska W. M. te Loo
Summary: Knowledge about adverse drug reactions (ADRs) is crucial for drug safety in pediatric patients, but underreporting of ADRs is a serious problem. This study aimed to increase the quantity of ADR reporting while maintaining or improving the quality. By educating healthcare providers and introducing an active supporting system, the quantity of ADR reports significantly increased without compromising the quality. This study suggests that an active reporting system has the potential to enhance our knowledge about ADRs in pediatric patients.
Article
Health Care Sciences & Services
Andreas Sandberg, Veera Salminen, Susanna Heinonen, Mia Siven
Summary: The study found that healthcare professionals in Finland have under-reporting issues when it comes to reporting adverse drug reactions (ADRs), mainly due to the reactions being already known or unclear reporting procedures. Training, information campaigns, and reporting reminders can help enhance ADR reporting rates.
Article
Pharmacology & Pharmacy
Faris El-Dahiyat, Khawla Abu Hammour, Rana Abu Farha, Qusai Manaseer, Ala'a Al Momanee, Aya Allan, Rama Alkhawaldeh
Summary: The study aimed to evaluate the knowledge, attitudes, and practice of the general public regarding Adverse Drug Reactions (ADRs) reporting and pharmacovigilance in Jordan. A survey was conducted using social media platforms, and the results showed that the participants had fair knowledge about ADRs but lacked awareness of the Jordan National Pharmacovigilance Centre (JNPC). Therefore, educational activities and intervention programs are needed to raise awareness about the JNPC and ensure safe medication use in Jordan.
SAUDI PHARMACEUTICAL JOURNAL
(2023)
Article
Pharmacology & Pharmacy
Dongxuan Li, Jinghui Gou, Jun Zhu, Tongyan Zhang, Feng Liu, Daojun Zhang, Liyang Dai, Wenjun Li, Qinglong Liu, Chunmeng Qin, Qian Du, Songqing Liu
Summary: This study provides a comprehensive landscape of culprit-drugs for severe cutaneous adverse reactions (SCARs) by analyzing reports from the FDA Adverse Event Reporting System database. It reveals the risk characteristics of different drugs and may help optimize patient management.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Meiwen van der Boom, Florence van Hunsel
Summary: The vaccination campaign for monkeypox virus in the Netherlands resulted in the collection of adverse event reports related to the vaccine. The majority of these reports were focused on injection site reactions and general systemic reactions, which aligns with the manufacturer's product information.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Urology & Nephrology
Salvatore Crisafulli, Paola Maria Cutroneo, Katia Verhamme, Carmen Ferrajolo, Vincenzo Ficarra, Laura Sottosanti, Valentina Di Giovanni, Edoardo Spina, Gianluca Trifiro
Summary: In this analysis of the Italian spontaneous reporting system database, five new signals of urinary retention were identified for dapagliflozin, gabapentin, lithium, celecoxib, and piroxicam, requiring further evaluation.
EUROPEAN UROLOGY FOCUS
(2022)
Article
Pharmacology & Pharmacy
Cristina Monteiro, Samuel Silvestre, Ana Paula Duarte, Gilberto Alves
Summary: The study found that suspected ADRs in older patients with diabetes mellitus were often serious and mostly associated with drugs used for diabetes treatment. The most common ADRs reported were hypoglycemia and lactic acidosis.
EXPERT OPINION ON DRUG SAFETY
(2021)
Article
Multidisciplinary Sciences
Richard Osei Buabeng, Paul Dsane-Aidoo, Yaw K. Asamoah, Delia Akosua Bandoh, Yvonne Adu Boahen, George Tsey Sabblah, Delese Mimi Darko, Charles Noora Lwanga, Donne Kofi Ameme, Ernest Kenu
Summary: This study evaluated the ADRSS in the Ho Municipality in Ghana and found that there was under-reporting of ADRs. The ADRSS showed strengths in certain aspects, but there were still issues with flexibility and timeliness.
Article
Endocrinology & Metabolism
Lulu Liu, Jia Chen, Lei Wang, Chen Chen, Li Chen
Summary: This study found that GLP-1 RAs were significantly associated with gastrointestinal AEs, with liraglutide, dulaglutide, and semaglutide contributing the most. Semaglutide had the highest risk of nausea, diarrhea, vomiting, constipation, and pancreatitis, while liraglutide had the highest risk of upper abdominal pain. Most gastrointestinal AEs tended to occur within one month.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Letter
Rheumatology
Julien Maquet, Margaux Lafaurie, Laurent Sailler, Maryse Lapeyre-Mestre, Guillaume Moulis
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Pharmacology & Pharmacy
Yoann Zelmat, Cecile Conte, Pernelle Noize, Clementine Vabre, Marie Pajiep, Margaux Lafaurie, Maryse Lapeyre-Mestre, Fabien Despas
Summary: This study used the French National Healthcare Database to identify the protein kinase inhibitors (PKIs) most frequently associated with the development of heart failure (HF). The study found a significant increase in the incidence of HF for six PKIs. Sensitivity analyses confirmed the results for four of these PKIs.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Lena Blayac, Camille Ponte, Monique Lavaud, Joelle Micallef, Maryse Lapeyre-Mestre
Summary: This study used data from the OPPIDUM survey from 2005 to 2018 to describe the changes in illicit substance use or diverted prescription drug use among pregnant women visiting addiction care centers in France. The study found a significant increase in the proportion of pregnant women using cannabis and cocaine, while the use of heroin significantly decreased. The results of this study are important for adapting prevention and care measures for pregnant women.
Article
Pharmacology & Pharmacy
Maryse Lapeyre-Mestre
Summary: The epidemiology of substance use disorders shows a male predominance, with women being neglected in research studies. However, women, especially young women, appear to be more vulnerable to the adverse effects of psychoactive substances such as opioids, benzodiazepines, cannabis, and nitrous oxide. It is crucial to consider gender in addiction surveillance and drug safety, even for substances primarily used by males. Additionally, specific prevention and care strategies need to be developed for the adequate management of women.
Article
Geriatrics & Gerontology
Anais Couret, Maryse Lapeyre-Mestre, Eugenie Gombault-Datzenko, Axel Renoux, Helene Villars, Virginie Gardette
Summary: This study aims to describe the healthcare use patterns of elderly individuals before being diagnosed with Alzheimer's Disease and Related Diseases (ADRD), in order to inform future medical actions.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY
(2023)
Editorial Material
Pharmacology & Pharmacy
Maryse Lapeyre-Mestre
Article
Substance Abuse
Thomas Soeiro, Vincent Pradel, Maryse Lapeyre-Mestre, Joelle Micallef
Summary: This study aimed to assess doctor-shopping behavior for psychoactive prescription drugs in France over a 10-year period. Using a repeated cross-sectional design and an algorithm to detect overlapping prescriptions, the study found that opioids, benzodiazepines, and Z-drugs had the highest proportions of doctor-shopping.
Article
Psychology, Clinical
Aurelie Aquizerate, Edouard-Jules Laforgue, Marion Istvan, Morgane Rousselet, Marie Gerardin, Emilie Jouanjus, Frederic Libert, Anne-Sylvie Caous, Samira Djezzar, Alexandra Boucher, Amelie Daveluy, Celine Eiden, Bernard Fauconneau, Christine Fournier-Choma, Valerie Gibaja, Clemence Lacroix, Maryse Lapeyre-Mestre, Reynald Le Boisselier, Bruno Revol, Marylene Guerlais, Caroline Victorri-Vigneau
Summary: This article presents addictovigilance data on the abuse, dependence, and misuse profiles of zopiclone in France, highlighting an increase in usage due to regulatory measures targeting zolpidem. It emphasizes the need for caution among prescribers when providing zopiclone prescriptions.
INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION
(2023)
Article
Pharmacology & Pharmacy
Romain Barus, Francois Montastruc, Claire de Canecaude, Haleh Bagheri, Agnes Sommet, Maryse Lapeyre-Mestre
Summary: This study analyzed the pharmacovigilance database of the World Health Organization and found an association between dental problems and sublingual/buccal buprenorphine. Compared to other buprenorphine formulations and methadone, sublingual/buccal buprenorphine had a higher reporting rate of dental problems. However, these findings do not undermine the benefits of sublingual/buccal buprenorphine in the treatment of opioid use disorders.
EXPERT OPINION ON DRUG SAFETY
(2023)
Meeting Abstract
Pharmacology & Pharmacy
L. Pochard, R. Le Boisselier, A. Batisse, H. Peyriere, A. Aquizerate, A. Boucher, B. Revol, A. Daveluy, M. Lapeyre-Mestre, E. Frauger, J. Micallef
FUNDAMENTAL & CLINICAL PHARMACOLOGY
(2023)
Meeting Abstract
Pharmacology & Pharmacy
M. Tambon, B. Montarnal, M. Lepetit, M. Lapeyre-Mestre
FUNDAMENTAL & CLINICAL PHARMACOLOGY
(2023)
Meeting Abstract
Pharmacology & Pharmacy
A. Ardillon, A. Testud, V. Fernandez, M. Lapeyre-Mestre, J. M. Delile, C. Payet, M. Viprey
FUNDAMENTAL & CLINICAL PHARMACOLOGY
(2023)
Meeting Abstract
Pharmacology & Pharmacy
E. Cifuentes-Castro, E. Ferrer, S. Puech, M. Lapeyre-Mestre
FUNDAMENTAL & CLINICAL PHARMACOLOGY
(2023)
Meeting Abstract
Pharmacology & Pharmacy
E. Jouanjus, M. Lapeyre-Mestre
FUNDAMENTAL & CLINICAL PHARMACOLOGY
(2023)
Meeting Abstract
Pharmacology & Pharmacy
M. Lafaurie, J. Maquet, M. Michel, M. Lapeyre-Mestre, G. Moulis
FUNDAMENTAL & CLINICAL PHARMACOLOGY
(2023)
